News

CADTH recently experienced problems with its website hosting platform that prevented users from downloading documents from cadth.ca – including draft reimbursement recommendations and stakeholder feedback forms. The issue has been resolved and all documents on our website are now accessible to…
CADTH is pleased to announce the introduction of the Real-World Evidence (RWE) Guidance Working Group which reports to the Real-World Evidence Steering Committee. The objective of this Guidance Working Group is to develop clear and comprehensive guidance on the conduct, reporting, and appraising of…
Held in April or May every year since 2005, the CADTH Symposium has traditionally been a spring event. Because of the COVID-19 pandemic, the 2020 CADTH Symposium was delayed until late fall and we continued with a fall date in 2021. Now we are preparing for a return to the CADTH Symposium’s…
CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation (PMDE) Network. Collaborators will bring additional expertise to the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space. The…
CADTH is pleased to announce the release of a new report entitled Building Toward a Potential Pan-Canadian Formulary: A Report From the Advisory Panel. In July 2021, the Government of Canada approached CADTH to develop a recommended framework for creating and managing a potential pan-Canadian…
CADTH is undertaking an innovative review for an antiviral treatment to address the recent monkeypox outbreaks. Monkeypox has become a serious public health issue around the globe. According to WHO, the most recent case fatality ratio from monkeypox infection is about 3% to 6%. The causes of death…
CADTH is pleased to announce the 4 successful Core Network Partners of its inaugural Post-Market Drug Evaluation (PMDE) Network. Core Network Partners will be the foundation of the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space…
June 1, 2022 – CADTH, the pan-Canadian health technology assessment body, will host a national roundtable on models of care for post–COVID-19 condition on June 1, 2022. Post–COVID-19 condition, or long COVID, is characterized by persistent or lingering symptoms that continue for weeks, months, or…
CADTH is expanding its Scientific Advice program to include applications for advice on real-world evidence (RWE) generation plans after protocols for pivotal trials have been finalized. This is an opportunity for pharmaceutical companies to enhance their engagement with CADTH regarding RWE. The…
A message from David Agnew, Chair of the CADTH Board of Directors, and Suzanne McGurn, President and CEO of CADTH We’re pleased to share Ahead of the Curve: Shaping Future-Ready Heath Systems, CADTH’s new 3-year strategic plan.  Our new strategic plan situates CADTH at the heart of a new, ever-…
CADTH is seeking nominations for its expert and advisory committees. We are currently accepting applications from individuals with significant expertise in the Canadian health care system who are interested in helping support health care decision-makers in making informed choices about health…
Proposals aim to help improve the accessibility and appropriate use of publicly funded drugs CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process for drug class reviews. Non-Sponsored Reimbursement Reviews Currently, a sponsor (a…